In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Inamed and Medicis Change the Face of the Aesthetic Market

Executive Summary

The $2.8 billion merger of Medicis Pharmaceutical Corp. a specialty pharma focusing on dermatology with sales of $303 million, and Inamed Corp., a cosmetic surgery company with sales of $384 million creates the largest plure-play aesthetics company focusing on physician markets, and a base for future consolidation in a fragmented and rapidly growing market.

You may also be interested in...

Sientra Looks Good: $80 million Series B Could Help Build Platform

A deep-pocketed syndicate--Orbimed Advisors, Clarus Ventures, TIAA-CREF and Goldman Sachs--supply $80 million to start Sientra, a seller of silicone breast implants and other aesthetics devices.

Beauty: In the Eye of the Stakeholder

A $12-billion market and growing, the field of aesthetic medicine has exploded with new treatments and techniques for improving and restoring the quality, health and appearance of aging skin. Techniques such as tissue tightening, skin resurfacing, cellulite treatments, dermal augmentation, and fat removal are just some of the new advancements in aesthetic medicine that were highlighted at the 2007 American Academy of Dermatology meeting.

Bidding War for the Aesthetic Market's Only Pure Play

The aesthetic market is becoming somewhat incestuous, with all of its major players current embroiled in some sort of takeover attempt on the businesses of the others. Back in March, dermatology specialist Medicis made an offer to acquire Inamed, the only pure-play in the medical aesthetics market. Some months later, Mentor, Inamed's rival in breast implants, made an offer for Medicis. Now Allergan, "the Botox company," is vying for Inamed with what it believes is a better offer. That all four publicly traded companies are trying to merge with one another highlights just how hot the aesthetics market is today. The bidding war also highlights the unique characteristics of the medical aesthetics specialty, in terms of the blurring between devices and drugs.

Related Content

Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts